{"filing":{"accession_number":"0001638833-26-000074","cik":"0001638833","ticker":"SGRY","company_name":"Surgery Partners, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"sgry-20260810.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1638833/000163883326000074/sgry-20260810.htm"},"events":[{"id":26366,"run_id":23957,"accession_number":"0001638833-26-000074","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"Surgery Partners issued a press release and earnings presentation on August 10, 2026 announcing second quarter and year-to-date 2026 financial results, including revenues of $848.9 million, net loss of $15.0 million, and Adjusted EBITDA of $125.2 million, with reaffirmation of full-year 2026 guidance of $3.35–$3.45 billion in revenue and at least $530 million in Adjusted EBITDA.","company_name":"Surgery Partners, Inc.","ticker":"SGRY","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27460,"accession_number":"0001638833-26-000074","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Surgery Partners issued a press release on August 10, 2026 announcing second quarter and year-to-date 2026 financial results, including revenues, net loss, Adjusted EBITDA, and full-year 2026 guidance reaffirmation. The disclosure includes detailed financial tables, operating metrics, and management commentary on quarterly performance. This is a standard earnings release disclosure under Item 2.02 of Form 8-K, attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:32:55.114880+00:00","company_name":"","ticker":null,"filing_date":""},{"id":27461,"accession_number":"0001638833-26-000074","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure announces Surgery Partners' second quarter 2026 financial results, including revenue of $848.9 million, net loss of $15.0 million, and Adjusted EBITDA of $125.2 million, with a press release (EX-99.1) and earnings presentation (EX-99.2) furnished as exhibits. The company reaffirmed full-year 2026 guidance of $3.35–$3.45 billion in revenue and at least $530 million in Adjusted EBITDA. This is a standard quarterly earnings disclosure material to investors assessing the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:32:55.114880+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27460,"accession_number":"0001638833-26-000074","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Surgery Partners issued a press release on August 10, 2026 announcing second quarter and year-to-date 2026 financial results, including revenues, net loss, Adjusted EBITDA, and full-year 2026 guidance reaffirmation. The disclosure includes detailed financial tables, operating metrics, and management commentary on quarterly performance. This is a standard earnings release disclosure under Item 2.02 of Form 8-K, attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:32:55.114880+00:00","company_name":"Surgery Partners, Inc.","ticker":"SGRY","filing_date":"2026-08-10"},{"id":27461,"accession_number":"0001638833-26-000074","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure announces Surgery Partners' second quarter 2026 financial results, including revenue of $848.9 million, net loss of $15.0 million, and Adjusted EBITDA of $125.2 million, with a press release (EX-99.1) and earnings presentation (EX-99.2) furnished as exhibits. The company reaffirmed full-year 2026 guidance of $3.35–$3.45 billion in revenue and at least $530 million in Adjusted EBITDA. This is a standard quarterly earnings disclosure material to investors assessing the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:32:55.114880+00:00","company_name":"Surgery Partners, Inc.","ticker":"SGRY","filing_date":"2026-08-10"}]}